ClinicalTrials.gg
CompletedNCT03443414Updated Jun 4, 2019Results posted

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

A Phase 2 interventional study of RPL554 suspension and Placebo in COPD, sponsored by Verona Pharma plc. Completed at 49 sites in 6 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2017, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 15
405 · median 79
Started
2017
with 1 other
Phase 2
8 of 15
none open now
Registered
4th of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 4th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.

Read the detailed description

RPL554 is a dual inhibitor of PDE3 and PDE4 which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator effects. PDE4 inhibitors (administered orally) have, however been associated with unfavorable gastrointestinal side effects such as nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss. Dual PDE3/PDE4 inhibitors (administered by inhalation) have exhibited both bronchodilator and anti-inflammatory actions, with a more favorable side effect profile. It is plausible that increased efficacy with reduced side effects may be achievable with administration of a dual PDE3/4 inhibitor by the inhaled route compared to orally administered PDE3 or PDE4 inhibitors.

The purpose of this study is to investigate the dose response of RPL554 in patients with COPD over 4 weeks. This length of time should allow for study of the bronchodilator response, measured predominantly by the peak forced expiratory volume in one second (FEV1), and the anti-inflammatory response, as measured predominantly by trough FEV1.

03

Conditions studied

  • COPD

Keywords

  • COPD, bronchodilation, FEV1
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide
  • Male or female aged 40 to 75 years
  • Meeting specified requirements
  • 12-lead with heart rate 50-90 beats per minute, corrected using Fridericia's formula (QTcF) ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no abnormalities
  • Capable of complying with all study restrictions and procedures, including ability to use the study nebulizer correctly.
  • (BMI) 18 to 35 kg/m2 and minimum weight 45 kg.
  • diagnosis with symptoms compatible with COPD for at least 1 year
  • Clinically stable COPD in the previous 4 weeks
  • Ability to perform acceptable and reproducible spirometry.
  • Post-bronchodilator spirometry at screening must demonstrate /forced vital capacity (FVC) ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal
  • Chest X-ray (posterior-anterior) at screening, or chest X-ray, magnetic resonance imaging (MRI) or computed tomography (CT) scan in the last 12 months, showing no abnormalities which are both clinically significant and unrelated to COPD.
  • Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  • Current and former smokers with a smoking history of ≥10 pack years.
  • Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication.

Exclusion criteria

Exclusion Criteria:

  • A history of life-threatening including Intensive Care Unit admission and requiring intubation.
  • COPD exacerbation requiring oral in the previous 3 months
  • A history of one or more hospitalizations for COPD in the previous 6 months
  • Lower respiratory tract infection treated with antibiotics in the previous 3 months
  • Evidence of cor pulmonale or pulmonary hypertension.
  • Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
  • Previous lung resection or lung reduction surgery.
  • Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) in the previous 3 months and throughout the study.
  • Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Visit 1) and remains stable during the trial.
  • A history of, or reason to believe a subject has, drug or alcohol abuse in the previous 3 years.
  • Received an experimental drug within 30 days or five half-lives of the first dose
  • Prior exposure to RPL554.
  • Women who are pregnant or breast-feeding.
  • Patients with a history of current uncontrolled disease that the Investigator believes are clinically significant.
  • myocardial infarction in the previous 6 month; congestive heart failure, a history of unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
  • Use of oral beta blockers.
  • Major surgery (requiring general anesthesia) in the previous 6 weeks, lack of full recovery from surgery at screening, or planned surgery through the end of the study.
  • History of of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
  • Clinically significant abnormal values for safety laboratory tests
  • Significant non-compliance in previous studies or with prescribed medications.
  • Requirement for oxygen therapy, even on an occasional basis.
  • Known to RPL554 or its /components.
  • Abnormal clinically significant 12 lead Holter findings,
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    0.75 mg RPL554

    Drug: RPL554 suspension

  • Experimental
    1.5 mg RPL554

    Drug: RPL554 suspension

  • Experimental
    3 mg RPL554

    Drug: RPL554 suspension

  • Experimental
    6 mg RPL554

    Drug: RPL554 suspension

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4

    Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.

    Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).

Secondary outcomes

  1. Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4

    Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.

    Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).

  2. Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4

    Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC\[0-12\]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.

    Time frame: Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4).

  3. Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4

    Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.

    Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).

  4. Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4

    Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.

    Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).

  5. Number of Patients With Treatment Emergent Adverse Events (TEAEs)

    The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death. All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.

    Time frame: Up to end of study (approximately 6 weeks)

07

Results

Posted Jun 4, 2019

Participant flow

405 adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) were randomized into this double-blind, multicenter study, and 403 received study medication. Patients were recruited to 47 study centers in Bulgaria, Czech Republic, Germany, Poland, Romania and the United Kingdom.

Participant flow — Overall Study
MilestoneRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Started8281828080
Received treatment8181828079
Completed7178767575
Not completed113655
Withdrew: Adverse event60423
Withdrew: Withdrawal by subject32221
Withdrew: Death01010
Withdrew: Reason not specified20001

Outcome measures

PrimaryMean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4

Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.

Time frame:
Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Reported as:
Least squares mean · Liters
Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4
LitersRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 40.203 (0.152 to 0.253)0.209 (0.160 to 0.258)0.257 (0.208 to 0.306)0.196 (0.147 to 0.246)0.057 (0.007 to 0.106)
Statistical analysis
  • RPL554 6.0 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.139 · 95% CI 0.069 to 0.210
  • RPL554 3.0 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.200 · 95% CI 0.131 to 0.270
  • RPL554 1.5 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.153 · 95% CI 0.083 to 0.222
  • RPL554 0.75 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.146 · 95% CI 0.075 to 0.216
SecondaryMean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4

Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.

Time frame:
Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Reported as:
Least squares mean · Liters
Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4
LitersRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 40.007 (-0.038 to 0.053)-0.019 (-0.063 to 0.025)0.040 (-0.003 to 0.084)-0.026 (-0.071 to 0.018)-0.028 (-0.072 to 0.016)
Statistical analysis
  • RPL554 6.0 mg vs Placebo · MMRM · p = =0.953 · Ls mean difference: 0.002 · 95% CI -0.061 to 0.065
  • RPL554 3.0 mg vs Placebo · MMRM · p = =0.032 · Ls mean difference: 0.068 · 95% CI 0.006 to 0.130
  • RPL554 1.5 mg vs Placebo · MMRM · p = =0.773 · Ls mean difference: 0.009 · 95% CI -0.053 to 0.072
  • RPL554 0.75 mg vs Placebo · MMRM · p = =0.272 · Ls mean difference: 0.035 · 95% CI -0.028 to 0.099
SecondaryMean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4

Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC\[0-12\]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.

Time frame:
Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4).
Reported as:
Least squares mean · Liters
Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4
LitersRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Day 10.088 (0.058 to 0.117)0.077 (0.048 to 0.107)0.103 (0.074 to 0.132)0.095 (0.065 to 0.125)0.008 (-0.022 to 0.038)
Week 40.039 (-0.007 to 0.085)0.052 (0.008 to 0.096)0.085 (0.040 to 0.130)0.031 (-0.014 to 0.076)-0.033 (-0.079 to 0.012)
Statistical analysis
  • RPL554 6.0 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.087 · 95% CI 0.045 to 0.129
  • RPL554 3.0 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.095 · 95% CI 0.053 to 0.137
  • RPL554 1.5 mg vs Placebo · MMRM · p = =0.001 · Ls mean difference: 0.070 · 95% CI 0.028 to 0.112
  • RPL554 0.75 mg vs Placebo · MMRM · p = <0.001 · Ls mean difference: 0.080 · 95% CI 0.038 to 0.122
  • RPL554 6.0 mg vs Placebo · MMRM · p = =0.048 · Ls mean difference: 0.065 · 95% CI 0.001 to 0.129
  • RPL554 3.0 mg vs Placebo · LS mean difference · p = <0.001 · Ls mean difference: 0.119 · 95% CI 0.055 to 0.183
  • RPL554 1.5 mg vs Placebo · MMRM · p = =0.008 · Ls mean difference: 0.085 · 95% CI 0.022 to 0.149
  • RPL554 0.75 mg vs Placebo · MMRM · p = =0.028 · Ls mean difference: 0.072 · 95% CI 0.008 to 0.137
SecondaryMean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4

Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.

Time frame:
Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4
Units on a scaleRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
E-RS Total Score-1.07 (-2.00 to -0.14)-1.26 (-2.16 to -0.35)-0.80 (-1.69 to 0.10)-0.92 (-1.81 to -0.02)1.19 (0.30 to 2.08)
E-RS Breathlessness Score-0.46 (-0.92 to -0.01)-0.63 (-1.07 to -0.18)-0.48 (-0.92 to -0.04)-0.48 (-0.92 to -0.04)0.47 (0.03 to 0.90)
E-RS Cough/Sputum Score-0.22 (-0.50 to 0.07)-0.30 (-0.58 to -0.03)-0.14 (-0.41 to 0.13)-0.21 (-0.48 to 0.06)0.36 (0.09 to 0.63)
E-RS Chest Symptoms Score-0.39 (-0.70 to -0.08)-0.32 (-0.62 to -0.02)-0.19 (-0.48 to 0.11)-0.22 (-0.52 to 0.07)0.35 (0.05 to 0.64)
SecondaryMean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4

Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.

Time frame:
Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4
Units on a scaleRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
SGRQ-C Total score-2.56 (-5.13 to 0.02)-3.18 (-5.72 to -0.65)-2.63 (-5.24 to -0.01)-3.01 (-5.51 to -0.51)-0.33 (-2.90 to 2.23)
SGRQ-C Symptoms score-4.73 (-7.99 to -1.46)-1.89 (-5.11 to 1.33)-2.17 (-5.50 to 1.17)-4.33 (-7.51 to -1.16)1.25 (-2.02 to 4.51)
SGRQ-C Activity score-2.19 (-5.30 to 0.91)-4.28 (-7.34 to -1.23)-2.70 (-5.85 to 0.46)-2.75 (-5.76 to 0.27)-2.16 (-5.25 to 0.94)
SGRQ-C Impact score-1.73 (-4.91 to 1.46)-2.93 (-6.06 to 0.20)-2.96 (-6.20 to 0.28)-2.80 (-5.89 to 0.29)0.11 (-3.07 to 3.28)
SecondaryNumber of Patients With Treatment Emergent Adverse Events (TEAEs)

The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death. All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.

Time frame:
Up to end of study (approximately 6 weeks)
Reported as:
Number · Patients
Number of Patients With Treatment Emergent Adverse Events (TEAEs)
PatientsRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Any TEAE2736292931
Any drug-related TEAE81112810
Any severe TEAE41212
Any serious TEAE22111
Any serious drug-related TEAE11000
Any TEAE leading to drug interruption10100
Any TEAE leading to drug discontinuation61422
Any TEAE leading to death01010

Adverse events

Collected over TEAEs were collected from the first dose of investigational product up to 2 weeks after the end of the study (Visit 6) (approximately 6 weeks).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RPL554 0.75 mg0/81 (0%)2/81 (2.5%)20/81 (24.7%)
RPL554 1.5 mg1/81 (1.2%)2/81 (2.5%)25/81 (30.9%)
RPL554 3.0 mg0/82 (0%)1/82 (1.2%)24/82 (29.3%)
RPL554 6.0 mg1/80 (1.3%)1/80 (1.3%)19/80 (23.8%)
Placebo0/79 (0%)1/79 (1.3%)25/79 (31.6%)
Most frequent serious events
Most frequent serious events
EventRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
Angina pectorisCardiac disorders0/810/810/820/801/79
DeathGeneral disorders0/810/810/821/800/79
Mitral valve incompetenceCardiac disorders0/811/810/820/800/79
Oesophageal varices haemorrhageGastrointestinal disorders1/810/810/820/800/79
Hepatic cirrhosisHepatobiliary disorders1/810/810/820/800/79
Hepatic encephalopathyNervous system disorders1/810/810/820/800/79
Completed suicidePsychiatric disorders0/811/810/820/800/79
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/810/810/820/800/79
Obstructive pancreatitisGastrointestinal disorders0/810/811/820/800/79
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlacebo
NasopharyngitisInfections and infestations2/814/814/825/807/79
HeadacheNervous system disorders4/814/817/824/803/79
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders4/815/813/823/806/79
CoughRespiratory, thoracic and mediastinal disorders4/814/816/821/801/79
DyspneaRespiratory, thoracic and mediastinal disorders3/811/811/821/805/79
HypertensionVascular disorders2/811/814/823/801/79
Productive coughRespiratory, thoracic and mediastinal disorders0/813/811/820/800/79
NauseaGastrointestinal disorders3/812/812/820/802/79
RhinitisInfections and infestations1/811/810/820/802/79
Supraventricular extrasystolesCardiac disorders0/811/810/821/802/79

Baseline characteristics

The baseline population consists of all randomized patients.

Age, Continuous
Age, Continuous(Years)RPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlaceboTotal Title
Mean63.6 ± 7.0563.4 ± 6.4062.5 ± 6.5162.9 ± 6.7363.5 ± 6.4463.2 ± 6.61
Sex: Female, Male
Sex: Female, Male(Participants)RPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlaceboTotal Title
Female2635373230160
Male5646454850245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlaceboTotal Title
Hispanic or Latino000000
Not Hispanic or Latino8281828080405
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RPL554 0.75 mgRPL554 1.5 mgRPL554 3.0 mgRPL554 6.0 mgPlaceboTotal Title
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White8281828080405
More than one race000000
Unknown or Not Reported000000
08

Study locations

49 sites
  • Clinic for pneumonology
    Pleven, Bulgaria
  • SHATPPD-Ruse EOOD
    Ruse, Bulgaria
  • Fifth MHAT - Sofia EAD
    Sofia, Bulgaria
  • MHAT 'Lyulin', EAD
    Sofia, Bulgaria
  • NMTH Tsar Boris III
    Sofia, Bulgaria
  • UMHAT 'Alexandrovska' EAD
    Sofia, Bulgaria
  • UMHAT 'Sveta Anna' AD
    Sofia, Bulgaria
  • Medical Center Nov
    Stara Zagora, Bulgaria
  • MediTrial s.r.o.
    Jindřichův Hradec, Czechia
  • Plicni stredisko Teplice
    Teplice, Czechia
  • Aerzte fuer Lungen- und
    Berlin, Germany
  • Charite Campus Mitte
    Berlin, Germany
  • emovis GmbH
    Berlin, Germany
  • Studienpraxis Berlin
    Berlin, Germany
  • IKF Pneumologie GmbH & Co. KG
    Frankfurt, Germany
  • Praxis Dr. Keller
    Frankfurt, Germany
  • Inamed GmbH
    Gauting, Germany
  • PRI Pulmonary Research
    Großhansdorf, Germany
  • Hamburger Institut fuer
    Hamburg, Germany
  • Gemeinschaftspraxis Dres
    Koblenz, Germany
  • POIS Leipzig GbR
    Leipzig, Germany
  • SALVUS UG Centre for Clinial Trials
    Leipzig, Germany
  • KLB Gesundheitsforschung
    Lübeck, Germany
  • Pneumologie Odeonsplatz
    Munich, Germany
  • Pneumologische Praxis Pasing
    München, Germany
  • Ballenberger Freytag Wenisch
    Neu Isenburg, Germany
  • Dr. Christian Schlenska
    Peine, Germany
  • Indywidualna Specjalistyczna
    Bialystok, Poland
  • CERMED
    Białystok, Poland
  • KLIMED Marek Klimkiewicz
    Bychawa, Poland
  • Silmedic sp. z o.o.
    Katowice, Poland
  • Grazyna Pulka Specjalistyczny
    Krakow, Poland
  • Malopolskie Centrum Alergologii
    Kraków, Poland
  • NZOZ Alergo-MEDSpecjalistyczna
    Poznań, Poland
  • ETG Network Sp z o o
    Skierniewice, Poland
  • Centrum Medyczne Pratia
    Warsaw, Poland
  • Mazowieckie Centrum Medyczne
    Warsaw, Poland
  • Specjalistyczna Opieka
    Wroclaw, Poland
  • Centrum Badan Klinicznych
    Wrocław, Poland
  • Centrum Terapii Wspólczesnej
    Łódź, Poland
  • Uniwersytecki Szpital Klin
    Łódź, Poland
  • S.C Angisan S.R.L
    Bragadiru, Romania
  • S.C Clinica Pneumomedica S.R.L
    Braşov, Romania
  • Fundatia Dr. Victor Babes
    Bucuresti, Romania
  • Spitalul Clinic de Urgenta
    Bucuresti, Romania
  • Spitalul Cl. Pneumoftiziologie
    Cluj-Napoca, Romania
  • Spitalul CldePneumoftiziologie
    Constanţa, Romania
  • Spitalul CldePneumoftiziologie
    Iaşi, Romania
  • Medicines Evaluation Unit
    Manchester, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jan 2018, 7 months.

Results were first posted in Jun 2019, 1 year 4 months after primary completion.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2018
First posted
Feb 23, 2018
StartActual
Jun 1, 2017
Primary completionActual
Jan 23, 2018
CompletionActual
Feb 7, 2018
Results first posted
Jun 4, 2019
Last update
Jun 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03443414
Lead sponsor
Verona Pharma plc
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Jun 1, 2017
Primary completion
Jan 23, 2018
Completion
Feb 7, 2018
Results posted
Jun 4, 2019
Last update
Jun 4, 2019

Study contacts

Dr Singh
principal investigator · Medicines Evaluation Unit (MEU)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion